Key Points
- Johanna Roberts sold 300 shares of Penumbra on Dec. 5 at an average price of $300.13 for $90,039, leaving her with 63,836 shares (a 0.47% reduction, valued at about $19.16M).
- Roberts has executed multiple insider sales this fall—totaling 3,900 shares across Oct. 1–Dec. 5 (notable moves: 1,800 shares on Nov. 25 and 600 shares on Dec. 1)—indicating a pattern of stake reductions.
- Market context: PEN is trading below its 12‑month high ($310) and was down ~2.6% (opened $287.11), while analysts hold a consensus "Moderate Buy" with a $305.69 target after Penumbra beat recent EPS and revenue estimates (revenue +17.8% YoY).
Penumbra, Inc. (NYSE:PEN - Get Free Report) EVP Johanna Roberts sold 300 shares of the stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $300.13, for a total value of $90,039.00. Following the completion of the transaction, the executive vice president owned 63,836 shares in the company, valued at approximately $19,159,098.68. The trade was a 0.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Johanna Roberts also recently made the following trade(s):
- On Monday, December 1st, Johanna Roberts sold 600 shares of Penumbra stock. The shares were sold at an average price of $294.94, for a total transaction of $176,964.00.
- On Tuesday, November 25th, Johanna Roberts sold 1,800 shares of Penumbra stock. The stock was sold at an average price of $300.06, for a total transaction of $540,108.00.
- On Monday, November 10th, Johanna Roberts sold 600 shares of Penumbra stock. The stock was sold at an average price of $266.98, for a total value of $160,188.00.
- On Wednesday, October 1st, Johanna Roberts sold 600 shares of Penumbra stock. The shares were sold at an average price of $249.70, for a total value of $149,820.00.
Penumbra Trading Down 2.6%
NYSE:PEN opened at $287.11 on Wednesday. Penumbra, Inc. has a 12-month low of $221.26 and a 12-month high of $310.00. The company has a current ratio of 6.73, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. The stock's 50 day simple moving average is $265.68 and its 200-day simple moving average is $258.25. The firm has a market cap of $11.24 billion, a P/E ratio of 68.69, a PEG ratio of 2.43 and a beta of 0.66.
Penumbra (NYSE:PEN - Get Free Report) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.90 by $0.07. Penumbra had a net margin of 12.30% and a return on equity of 11.35%. The firm had revenue of $354.69 million for the quarter, compared to analyst estimates of $340.77 million. During the same period last year, the firm posted $0.85 EPS. Penumbra's quarterly revenue was up 17.8% on a year-over-year basis. Equities analysts anticipate that Penumbra, Inc. will post 3.67 EPS for the current year.
Analyst Upgrades and Downgrades
PEN has been the topic of a number of recent analyst reports. Evercore ISI reaffirmed an "outperform" rating and set a $286.00 price target on shares of Penumbra in a research note on Thursday, November 6th. Wall Street Zen downgraded shares of Penumbra from a "buy" rating to a "hold" rating in a report on Saturday, November 1st. JPMorgan Chase & Co. increased their target price on shares of Penumbra from $265.00 to $275.00 and gave the company a "neutral" rating in a report on Thursday, November 6th. Weiss Ratings reiterated a "hold (c)" rating on shares of Penumbra in a research report on Monday. Finally, Truist Financial decreased their price target on Penumbra from $310.00 to $300.00 and set a "buy" rating on the stock in a research note on Wednesday, October 15th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $305.69.
Read Our Latest Report on PEN
Institutional Trading of Penumbra
A number of large investors have recently made changes to their positions in the stock. Mather Group LLC. purchased a new stake in shares of Penumbra during the third quarter worth about $25,000. Newbridge Financial Services Group Inc. purchased a new stake in Penumbra in the 2nd quarter worth approximately $30,000. Rothschild Investment LLC acquired a new position in Penumbra in the 3rd quarter valued at $40,000. Parkside Financial Bank & Trust lifted its stake in shares of Penumbra by 70.2% during the 2nd quarter. Parkside Financial Bank & Trust now owns 160 shares of the company's stock worth $41,000 after purchasing an additional 66 shares during the period. Finally, Covestor Ltd grew its position in shares of Penumbra by 53.0% in the third quarter. Covestor Ltd now owns 179 shares of the company's stock valued at $46,000 after purchasing an additional 62 shares during the period. Institutional investors and hedge funds own 88.88% of the company's stock.
Penumbra Company Profile
(
Get Free Report)
Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
